Protein Z-dependent protease inhibitor (ZPI) is present in loco in human breast cancer tissue

Thrombosis and Haemostasis

Volumn 104, Issue 1, 2010, Pages 183-185

  Sierko, Ewa ^a,b   Wojtukiewicz, Marek Z ^a,b   Ostrowska Cichocka, Krystyna ^a,b   Zimnoch, Lech ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b Regional Comprehensive Cancer Center in Bialystok   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; MESSENGER RNA; PROTEIN Z DEPENDENT PROTEASE INHIBITOR; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER TISSUE; ENDOTHELIUM CELL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTRADUCTAL CARCINOMA; LETTER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE;

BLOOD PROTEINS; BREAST NEOPLASMS; CARCINOMA, DUCTAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAMMARY GLANDS, HUMAN; RNA, MESSENGER; SERPINS; TUMOR MARKERS, BIOLOGICAL;

EID: 77954372982     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-09-0666     Document Type: Letter

References (26)

1. Carlson RW, Allred DC, Anderson BO, et al. Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2009; 7: 122-192.
2. Falanga A, Rickles FR. Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost 1999; 25: 173-182. (Pubitemid 29227146)
3. Zacharski LR, Wojtukiewicz MZ, Costantini V, et al. Pathways of coagulation/fibrinolysis activation in malignancy. Semin Thromb Hemost 1992; 18: 104-116.
4. Wojtukiewicz MZ, Sierko E, Rak J. Contribution of hemostatic system to angiogenesis in cancer. Semin Thromb Hemost 2004; 30: 5-20. (Pubitemid 38457297)
5. Wojtukiewicz MZ, Sierko E, Kisiel W. The role of hemostatic system inhibitors in malignancy. Semin Thromb Hemost 2007; 33: 621-641. (Pubitemid 350157006)
6. Broze GJ Jr, Miletich JP. Human protein Z. J Clin Invest 1984; 73: 933-938.
7. Han X, Huang ZF, Fiehler R, et al. The protein Z-dependent protease inhibitor is a serpin. Biochemistry 1999; 38: 11073-11078. (Pubitemid 29411597)
8. Han X, Fiehler R, Broze GJ Jr. Characterization of protein Z-dependent protease inhibitor. Blood 2000; 96: 3049-3055.
9. Tabatabai A, Fiehler R, Broze GJ Jr. Protein Z circulates in plasma in a complex with protein Z-dependent protease inhibitor. Thromb Haemost 2001; 85: 655-660. (Pubitemid 32293702)
10. Hsu S, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981; 29: 577-580.
11. Sierko E, Wojtukiewicz MZ, Zimnoch L, et al. Expression of tissue factor pathway inhibitor (TFPI) in human breast and colon cancer tissue. Thromb Haemost 2010; 103: 198-204.
12. Komminoth P, Werner M. Target and signal amplification: approaches to increase the sensitivity of in situ hybridization. Histochem Cell Biol 1997; 108: 325-333.
13. Kasprzak A, Zabel M, Wysocki J, et al. Detection of DNA, mRNA and early antigen of the human cytomegalovirus (HCMV) using Immunomax technique in autopsy material of children with intrauterine infection. Virchows Arch 2000; 437: 482-490.
14. Sierko E, Sawicki Z, Hempel D, et al. The localization of components of coagulation system in breast cancer in loco. Onkologia Polska 2006; 9: 69-74.
15. Broze GJ Jr. Protein Z-dependent regulation of coagulation. Thromb Haemost 2001; 86: 8-13.
16. Kurer MA. Protein and mRNA expression of tissue factor pathway inhibitor-1 (TFPI-1) in breast, pancreatic and colorectal cancer cells. Mol Biol Rep 2007; 34: 221-224.
17. Amirkhosravi A, Meyer T, Amaya M, et al. The role of tissue factor pathway inhibitor in tumor growth and metastasis. Semin Thromb Hemost 2007; 33: 643-652.
18. Wojtukiewicz MZ, Zacharski LR, Memoli VA, et al. Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung. Cancer 1990; 65: 481-485. (Pubitemid 20058364)
19. Beaulieu LM, Church FC. Activated protein C promotes breast cancer cell migration through interactions with EPCR and PAR-1. Exp Cell Res 2007; 313: 677-687.
20. Cheng T, Liu D, Griffin JH, et al. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med 2003; 9: 338-342. (Pubitemid 36362790)
21. Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR-1-dependent sphingosine1-phosphate receptor-1 cross-activation. Blood 2005; 105: 3178-3184.
22. Wojtukiewicz MZ, Sierko E, Zimnoch L, et al. Immunohistochemical localization of tissue factor pathway inhibitor-2 in human tumor tissue. Thromb Haemost 2003; 90: 140-146.
23. Shang Y, Pan XY, Ding CP, et al. Clinical significance of protein Z detection in patients with malignant tumors. Ai Zheng 2005; 24: 1144-1147.
24. Vasse M, Denoyelle C, Corbière C, et al. Human endothelial cells synthesize protein Z, but not the protein Z dependent inhibitor. Thromb Haemost 2006; 95: 519-523.
25. Vairaktaris E, Serefoglou Z, Yapijakis C, et al. Coagulation- related factors, thrombomodulin and protein Z, are not associated with risk for oral cancer. Anticancer Res 2007; 27: 2449-2451.
26. Eroglu A, Ozturk A, Cam R, et al. Intron F G79A polymorphism of the protein Z gene in cancer patients with and without thrombosis. J Thromb Thrombolysis 2009; 27: 204-206.